Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Tildrakizumab Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Tildrakizumab Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Prefilled 100 mg/mL solution
      • 1.3.3 Type II
    • 1.4 Market Segment by Application
      • 1.4.1 Global Tildrakizumab Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Drug store
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Tildrakizumab Market Size
      • 2.1.1 Global Tildrakizumab Revenue 2014-2025
      • 2.1.2 Global Tildrakizumab Sales 2014-2025
    • 2.2 Tildrakizumab Growth Rate by Regions
      • 2.2.1 Global Tildrakizumab Sales by Regions 2014-2019
      • 2.2.2 Global Tildrakizumab Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Tildrakizumab Sales by Manufacturers
      • 3.1.1 Tildrakizumab Sales by Manufacturers 2014-2019
      • 3.1.2 Tildrakizumab Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Tildrakizumab Revenue by Manufacturers (2014-2019)
      • 3.2.2 Tildrakizumab Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Tildrakizumab Market Concentration Ratio (CR5 and HHI)
    • 3.3 Tildrakizumab Price by Manufacturers
    • 3.4 Key Manufacturers Tildrakizumab Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Tildrakizumab Market
    • 3.6 Key Manufacturers Tildrakizumab Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Prefilled 100 mg/mL solution Sales and Revenue (2014-2019)
      • 4.1.2 Type II Sales and Revenue (2014-2019)
    • 4.2 Global Tildrakizumab Sales Market Share by Type
    • 4.3 Global Tildrakizumab Revenue Market Share by Type
    • 4.4 Tildrakizumab Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Tildrakizumab Sales by Application

    6 United States

    • 6.1 United States Tildrakizumab Breakdown Data by Company
    • 6.2 United States Tildrakizumab Breakdown Data by Type
    • 6.3 United States Tildrakizumab Breakdown Data by Application

    7 European Union

    • 7.1 European Union Tildrakizumab Breakdown Data by Company
    • 7.2 European Union Tildrakizumab Breakdown Data by Type
    • 7.3 European Union Tildrakizumab Breakdown Data by Application

    8 China

    • 8.1 China Tildrakizumab Breakdown Data by Company
    • 8.2 China Tildrakizumab Breakdown Data by Type
    • 8.3 China Tildrakizumab Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Tildrakizumab Breakdown Data by Company
    • 9.2 Rest of World Tildrakizumab Breakdown Data by Type
    • 9.3 Rest of World Tildrakizumab Breakdown Data by Application
    • 9.4 Rest of World Tildrakizumab Breakdown Data by Countries
      • 9.4.1 Rest of World Tildrakizumab Sales by Countries
      • 9.4.2 Rest of World Tildrakizumab Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Sun Pharma
      • 10.1.1 Sun Pharma Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Tildrakizumab
      • 10.1.4 Tildrakizumab Product Introduction
      • 10.1.5 Sun Pharma Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Tildrakizumab Sales Channels
      • 11.2.2 Tildrakizumab Distributors
    • 11.3 Tildrakizumab Customers

    12 Market Forecast

    • 12.1 Global Tildrakizumab Sales and Revenue Forecast 2019-2025
    • 12.2 Global Tildrakizumab Sales Forecast by Type
    • 12.3 Global Tildrakizumab Sales Forecast by Application
    • 12.4 Tildrakizumab Forecast by Regions
      • 12.4.1 Global Tildrakizumab Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Tildrakizumab Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Tildrakizumab (trade name Ilumya (USA)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. In the United States, it is approved for the treatment of moderate-to-severe plaque psoriasis.
      In 2019, the market size of Tildrakizumab is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Tildrakizumab.

      This report studies the global market size of Tildrakizumab, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Tildrakizumab sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Sun Pharma
      ...

      Market Segment by Product Type
      Prefilled 100 mg/mL solution
      Type II

      Market Segment by Application
      Hospital
      Drug store

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Tildrakizumab status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Tildrakizumab manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Tildrakizumab are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now